Inside Big Pharma’s Stealth War on Drug Price Watchdog: Reuters Special Report

As evidence grew this spring that the drug remdesivir was helping COVID-19 patients, some Wall Street investors bet on analysts’ estimates that its maker, Gilead Sciences Inc., could charge up to $10,000 for the treatment. Then a small but increasingly …

from News – Insurance Journal